Kaposi Sarcoma in case of solid organ transplantation

Kaposi sarcoma (KS) is a soft tissue cancer that is related to several intrinsic and environ­mental factors. In the general population, KS is an extremely rare tumor, however, the risk of its development is substantially increased in immune compromised patients including patients with acquired immune deficiency syndrome (AIDS) and solid organ recipients. Genetic predisposition, seropositivity for human herpes virus type HHV, and increased HHV prevalence in the general population are some proposed factors for the development of KS. Middle East is reported as a highly prevalent region for the incidence of post-transplant KS, reports from Saudi Arabia, Egypt and Turkey indicate a high incidence of this disease. Kaposi sarcoma was first described by Moritz Kaposi in the 1870, the disease was a medical curiosity in Europe and the United States until the acquired immunodeficiency syndrome was recognized in 1981.

 

 

    Related Conference of Kaposi Sarcoma in case of solid organ transplantation

    October 30-30, 2020

    Genetics and Molecular biology

    Paris, France
    November 16-17, 2020

    International Conference on Genomics and Molecular Biology

    Lisbon, Portugal
    November 19-19, 2020

    Webinar on Biotechnology

    London, UK
    November 23-24, 2020

    International Conference on Toxicogenomics

    Bali, Indonesia
    December 07-08, 2020

    2nd World Congress on Cell and Structural Biology

    Sydney, Australia

    Kaposi Sarcoma in case of solid organ transplantation Conference Speakers

    Recommended Sessions

    Related Journals

    Are you interested in